48 patents
Page 3 of 3
Utility
PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
30 Sep 20
The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
Filed: 25 May 20
Utility
Pyrrolobenzodiazepine-antibody conjugates
21 Sep 20
The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
Filed: 24 Nov 15
Utility
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
27 Jul 20
Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
Filed: 30 Jan 18
Utility
Dosage Regimes for the Administration of an ANTI-CD19 Adc
3 Jun 20
Jay Marshall Feingold, David Rodney Ungar
Filed: 13 Jun 18
Utility
Combination Therapy with an Anti-axl Antibody-drug Conjugate
29 Apr 20
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
Filed: 19 Apr 18
Utility
Combination Therapy with an Anti-psma Antibody-drug Conjugate
29 Apr 20
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
Filed: 19 Apr 18
Utility
Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
23 Mar 20
Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein.
Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
Filed: 12 Nov 17
Utility
Combination therapy with an anti-axl antibody-drug conjugate
27 Jan 20
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
Filed: 20 Nov 18